{"id":3069,"date":"2022-03-16T11:15:19","date_gmt":"2022-03-16T11:15:19","guid":{"rendered":"http:\/\/dev.jatstudio.com\/gt1\/projects"},"modified":"2022-03-30T08:43:46","modified_gmt":"2022-03-30T08:43:46","slug":"projects","status":"publish","type":"page","link":"https:\/\/dev.jatstudio.com\/en\/gt1\/projects","title":{"rendered":"Projects"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Projects<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.\u00a0<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

COST Programme. Funded by European Union.<\/a><\/strong><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Reference | CA20121<\/a><\/strong><\/p>

Execution date | 19\/10\/2021 \u2013 18\/10\/2025<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Non-communicable diseases (NCDs) account for 77% of all deaths in Europe and remain the most prevalent and without effective therapy.<\/p>

The transcription factor NRF2 is a master regulator of multiple cytoprotective responses and a key molecular link among many NCDs. It provides a unique strategy for drug development and repurposing that is now starting to be translated to the pharmacological and clinical arena.<\/p>

This Action will build a network of excellence for integrating and spreading the existing knowledge and providing innovative services, drugs and tools related to NRF2-pharmacology, with the final goal of boosting the translation to the European industry sector.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Development of NRF2-activating drugs for innovative therapies for Alzheimer's disease<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Programas de actividades de I+D entre grupos de investigaci\u00f3n de la Comunidad de Madrid en Biomedicina (2017).<\/a><\/strong><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Reference | S2017\/BMD-3827<\/a><\/strong><\/p>

Execution date | 01\/01\/2018 \u2013 30\/06\/2022<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tAlzheimer\u2019s disease (AD), the main cause associated with dementia, is the most prevalent neurodegenerative disease (NDD) nowadays, with more than 46 million people affected worldwide. Considering its direct relation with aging, this figure is estimated to surpass the amount of 100 million by year 2050.\r\nAD has a tremendous social impact, due to the loss of life quality and autonomy (both for the patient and their relatives \/ caregivers), and also a huge economic burden for national health systems, currently estimated at 818 billion dollars globally.\r\nDespite all the human and economic effort invested, in the last 15 years no new drugs have been incorporated to the clinical practice for the treatment of AD, and the efficacy of those that are commonly used is not satisfactory.\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Interplay between neuroinflammation, oxidative stress and proteostasis: new targets to tackle neurodegeneration in AD (NewTargets4AD)<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tR+D+i Projects \u00abResearch Challenges\u00bb 2018. FEDER\/Ministry of Science and Innovation\/ Research Agency.<\/a><\/strong>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Reference | RTI2018-095793-B-I00<\/a><\/strong><\/p>

Execution date | 01\/01\/2018 \u2013 30\/06\/2022<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\tAmong the different neurodegenerative diseases (NDDs), Alzheimers disease (AD) is the most common neurocognitive disorder with substantial social and economic impacts. To date, no new drug has qualified to be added to the current therapeutic arsenal that comprises cholinesterase inhibitors and the NMDA receptor antagonist memantine. There is accumulating knowledge indicating that chronic, unremitting, low grade<\/span>\r\n\r\nneuroinflammation, oxidative stress, mitochondrial dysfunction and altered proteostasis\/autophagy are interconnected processes that act in a coordinated and reverberating manner to cause neurodegeneration. We therefore hypothesize, that by acting on the latter systems, which are altered in the initial phases of neurodegeneration, the chances of having a better impact in preventing\/reducing disease progression may be higher. In this context, the proposed project will focus on how certain enzymes such HO-1 (regulation of inflammation\/oxidative stress), NADPH oxidase 4 (constitutive active enzyme responsible for producing reactive oxygen species) and PGC-alpha; (master regulator of mitochondrial biogenesis) impact on oxidative stress, neuroinflammation and autophagy flux markers to regulate neurodegeneration and dementia.\u00a0<\/span>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Imagen<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

RED2018\u2010102362\u2010T<\/a><\/strong>.<\/strong> Red de investigaci\u00f3n traslacional sobre la regulaci\u00f3n farmacol\u00f3gica de NRF2 en enfermedades no transmisibles. MINECO. PI. Antonio Cuadrado. UAM. 01\/12\/2019-1\/12\/2020.\u00a0<\/span><\/p>

SAF2015-63935R<\/a>.<\/strong>\u00a0Exploraci\u00f3n del eje alfa-7nAChR\/Nrf2\/HO-1 en la interacci\u00f3n microgl\u00eda-neurona y su impacto en los procesos de neurodegeneraci\u00f3n y neuroprotecci\u00f3n.\u00a0MINECO.\u00a0PI: Manuela G. L\u00f3pez. UAM. 01\/01\/2016 – 31\/12\/2018.\u00a0<\/p>

COST Action BM1203:EU-ROS<\/span>.\u00a0<\/span><\/a><\/strong>EU-ROS: The European Network on Oxidative Stress and Redox Biology\u00a0<\/span>Research.<\/span>\u00a0Coordinador: Andreas Daiber.\u00a0<\/span>05\/12\/2012-04\/12\/2016.\u00a0Manuela G. L\u00f3pez.\u00a0Miembro sustituto del Comit\u00e9 ejecutivo en representaci\u00f3n de Espa\u00f1a.\u00a0<\/p>

SAF2012-2332.<\/strong>Control colin\u00e9rgico de la neuroinflamaci\u00f3n y su participaci\u00f3n en la neuroprotecci\u00f3n. MINECO.\u00a0PI: Manuela G. L\u00f3pez. 01\/01\/2013-31\/12\/2015.\u00a0<\/p>

SAF2009-12150.<\/strong> Contribuci\u00f3n de los receptores nicot\u00ednicos a la neuroprotecci\u00f3n y a la\u00a0neuroinflamaci\u00f3n. MICINN. PI: Manuela G. L\u00f3pez. 01\/01\/2010 \u2013 31\/12\/2012.\u00a0<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Projects Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases.\u00a0 COST Programme. Funded by European Union. Reference | CA20121 Execution date | 19\/10\/2021 \u2013 18\/10\/2025 Non-communicable diseases (NCDs) account for 77% of all deaths in Europe and remain the most prevalent and without effective therapy. The transcription factor NRF2 is a master … Read more Projects<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":488,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/dev.jatstudio.com\/en\/wp-json\/wp\/v2\/pages\/3069"}],"collection":[{"href":"https:\/\/dev.jatstudio.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/dev.jatstudio.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/dev.jatstudio.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.jatstudio.com\/en\/wp-json\/wp\/v2\/comments?post=3069"}],"version-history":[{"count":11,"href":"https:\/\/dev.jatstudio.com\/en\/wp-json\/wp\/v2\/pages\/3069\/revisions"}],"predecessor-version":[{"id":3148,"href":"https:\/\/dev.jatstudio.com\/en\/wp-json\/wp\/v2\/pages\/3069\/revisions\/3148"}],"up":[{"embeddable":true,"href":"https:\/\/dev.jatstudio.com\/en\/wp-json\/wp\/v2\/pages\/488"}],"wp:attachment":[{"href":"https:\/\/dev.jatstudio.com\/en\/wp-json\/wp\/v2\/media?parent=3069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}